Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more
Agios Pharm (AGIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.081x
Based on the latest financial reports, Agios Pharm (AGIO) has a cash flow conversion efficiency ratio of -0.081x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-96.21 Million) by net assets ($1.19 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Agios Pharm - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Agios Pharm's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Agios Pharm Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Agios Pharm ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fujian Sunner Development Co Ltd
SHE:002299
|
0.145x |
|
Anhui Heli Co Ltd
SHG:600761
|
0.036x |
|
German American Bancorp Inc
NASDAQ:GABC
|
0.006x |
|
TravelSky Technology Limited
PINK:TSYHF
|
0.052x |
|
Qingdao Hanhe Cable Co Ltd
SHE:002498
|
0.031x |
|
HMS Networks AB (publ)
OTCGREY:HMNKF
|
0.066x |
|
Avepoint Inc
NASDAQ:AVPT
|
0.062x |
|
Mack-Cali Realty Corporation
F:WY4
|
0.011x |
Annual Cash Flow Conversion Efficiency for Agios Pharm (2011–2025)
The table below shows the annual cash flow conversion efficiency of Agios Pharm from 2011 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.19 Billion | $-372.98 Million | -0.313x | -23.57% |
| 2024-12-31 | $1.54 Billion | $-389.84 Million | -0.253x | +30.70% |
| 2023-12-31 | $811.02 Million | $-296.06 Million | -0.365x | -29.85% |
| 2022-12-31 | $1.10 Billion | $-309.48 Million | -0.281x | +10.83% |
| 2021-12-31 | $1.29 Billion | $-407.32 Million | -0.315x | +56.68% |
| 2020-12-31 | $399.50 Million | $-290.76 Million | -0.728x | -25.78% |
| 2019-12-31 | $640.53 Million | $-370.62 Million | -0.579x | -30.68% |
| 2018-12-31 | $687.54 Million | $-304.42 Million | -0.443x | +41.71% |
| 2017-12-31 | $375.50 Million | $-285.23 Million | -0.760x | -806.36% |
| 2016-12-31 | $358.59 Million | $38.56 Million | 0.108x | +148.23% |
| 2015-12-31 | $345.12 Million | $-76.95 Million | -0.223x | -59.42% |
| 2014-12-31 | $424.37 Million | $-59.35 Million | -0.140x | +67.39% |
| 2013-12-31 | $131.48 Million | $-56.40 Million | -0.429x | +62.00% |
| 2012-12-31 | $43.90 Million | $-49.55 Million | -1.129x | -368.27% |
| 2011-12-31 | $63.14 Million | $-15.22 Million | -0.241x | -- |